SMS Pharmaceuticals: CARE Ratings Reaffirms 'CARE A; Stable' Outlook on ₹570 Crore Facilities
SMS Pharmaceuticals Limited's long-term bank facilities of ₹570.07 crore have been reaffirmed with a 'CARE A; Stable' rating by CARE Ratings. The outlook was revised from Positive to Stable. Short-term facilities of ₹52.83 crore were reaffirmed at 'CARE A1'. The ratings consider FY26 audited and Q1FY27 performance.
Credit ratings are important for a company's borrowing capacity and cost of debt. While a reaffirmation is generally positive, the revision of outlook from Positive to Stable suggests a neutral to slightly positive impact, as it doesn't indicate a significant improvement but rather a maintenance of the current standing.
The reaffirmation of credit ratings with a stable outlook, and an enhancement in the amount of long-term facilities, indicates a positive assessment of the company's creditworthiness by the rating agency.
SMS Pharmaceuticals Limited has received a credit rating update from CARE Ratings Limited. The rating agency has reaffirmed the 'CARE A; Stable' rating for the company's long-term bank facilities, amounting to ₹570.07 crore. This represents an enhancement from the previously rated ₹350.87 crore. The outlook has been revised from Positive to Stable.
Additionally, the short-term bank facilities, totaling ₹52.83 crore, have also been reaffirmed with a 'CARE A1' rating.
These ratings are based on the company's operational and financial performance for FY26 (audited) and Q1FY27 (Abridged), and the potential impact on its credit profile. The detailed breakdown of the rated facilities includes various term loans and fund-based/non-fund-based limits from multiple banks, such as Export Import Bank of India, Axis Bank, IDBI Bank, State Bank of India, and RBL Bank Limited.
A plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.